Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-21
2011-12-27
Chung, Susannah (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S385000, C548S262200, C548S300100
Reexamination Certificate
active
08084481
ABSTRACT:
The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.
REFERENCES:
patent: 5276049 (1994-01-01), Himmelsbach et al.
patent: 5468448 (1995-11-01), Wahi et al.
patent: 5585394 (1996-12-01), Di Malta et al.
patent: 5681841 (1997-10-01), Himmelsbach et al.
patent: 6531142 (2003-03-01), Rabe et al.
patent: 6746989 (2004-06-01), Muller et al.
patent: 6762152 (2004-07-01), Muller et al.
patent: 6838415 (2005-01-01), Muller et al.
patent: 2002/0045651 (2002-04-01), Brenner et al.
patent: 2002/0172644 (2002-11-01), Haslwanter et al.
patent: 2003/0161790 (2003-08-01), Wahi et al.
patent: 2004/0071757 (2004-04-01), Rolf et al.
patent: 2006/0148779 (2006-07-01), Bell et al.
patent: 2008/0095863 (2008-04-01), Kabra et al.
patent: 2010/0261771 (2010-10-01), Bruggemeier et al.
patent: 2327784 (2008-03-01), None
patent: 051829 (1982-05-01), None
patent: 0412594 (1990-07-01), None
patent: 0533276 (1993-03-01), None
patent: 9931099 (1999-06-01), None
patent: 0100595 (2001-01-01), None
patent: WO-02/066447 (2002-08-01), None
patent: WO-2005/006892 (2005-01-01), None
patent: WO-2005/007112 (2005-01-01), None
patent: WO-2005/086836 (2005-09-01), None
patent: WO 2005/105779 (2005-11-01), None
patent: 2006066133 (2006-06-01), None
patent: 2006117657 (2006-11-01), None
R. W. Schrier, M.D. et al., “Hormones and Hemodynamics in Hear Failure,” New England Journal of Medicine, vol. 341, No. 8, (1999), pp. 577-585.
L. De Luca, M.D. et al., “Hyponatremia in Patients with Heart Failure,” American Journal of Cardiology 2005; 96 Supp., 19L-23L.
G. S. Francis, M.D. et al, “Comparison of Neuroendocrine Activation in Patients with Left Ventricular Dysfunction with and without Congestive Heart Failure,” Circulation, 1990; pp. 1724-1929.
P. Sanghi et al., “Vasopressin Antagonism: a Future Treatment Option in Heart Failure,” The European Society of Cardiology, 2005, pp. 538-543.
J. J. Bronson et al., “Discovery of the first Antibacterial Small Molecule Inhibitors of MurB,” Bioorganic & Medicinal Chemistry Letters 13, 2003, pp. 873-875.
Lemmens-Gruber, et al.: Vasopressin antagonists, Cell. Mol. Life Sci. 63 (2006) 1766-1779.
Tang et al.,: Vasopressin receptor antagonists in the management of acute heart failure, Expert Opin. Investig. Drugs, 2005, 14:5, pp. 593-600.
Palm et al., Vasopressin Antagonists as Aquaretic Agents for the Treatment of Hyponatremia, Am. J. Med. (2006) vol. 119 (7A) S87-S92.
U.S. Appl. No. 13/132,897, filed Jun. 15, 2009.
U.S. Appl. No. 12/727,044, filed Feb. 16, 2011.
Francis et al., “Comparison of Neuroendocrine Activation in Patients with Left Ventricular Dysfunction with and without Congestive Heart Failure,” Circulation 1990, vol. 82, 1724-1729.
English translation of WO 2001/00595, filed as U.S. Appl. No. 10/019,247 on Dec. 18, 2001.
Bender Eckhard
Brüggemeier Ulf
Flamme Ingo
Fürstner Chantal
Karthaus Dagmar
Bayer Pharma Aktiengesellschaft
Chung Susannah
King Karen B.
LandOfFree
Substituted arylimidazolone and triazolone as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted arylimidazolone and triazolone as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted arylimidazolone and triazolone as inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4302242